JP5785077B2 - 崩壊温度より高温での凍結乾燥 - Google Patents

崩壊温度より高温での凍結乾燥 Download PDF

Info

Publication number
JP5785077B2
JP5785077B2 JP2011522218A JP2011522218A JP5785077B2 JP 5785077 B2 JP5785077 B2 JP 5785077B2 JP 2011522218 A JP2011522218 A JP 2011522218A JP 2011522218 A JP2011522218 A JP 2011522218A JP 5785077 B2 JP5785077 B2 JP 5785077B2
Authority
JP
Japan
Prior art keywords
temperature
freeze
collapse
less
primary drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011522218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530524A5 (en11
JP2011530524A (ja
Inventor
チェサロヴ セルゲイ
チェサロヴ セルゲイ
デクソン ダン
デクソン ダン
ワーン ニコラス
ワーン ニコラス
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41401614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5785077(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2011530524A publication Critical patent/JP2011530524A/ja
Publication of JP2011530524A5 publication Critical patent/JP2011530524A5/ja
Application granted granted Critical
Publication of JP5785077B2 publication Critical patent/JP5785077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011522218A 2008-08-05 2009-08-05 崩壊温度より高温での凍結乾燥 Active JP5785077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8642608P 2008-08-05 2008-08-05
US61/086,426 2008-08-05
PCT/US2009/052852 WO2010017296A1 (en) 2008-08-05 2009-08-05 Lyophilization above collapse

Publications (3)

Publication Number Publication Date
JP2011530524A JP2011530524A (ja) 2011-12-22
JP2011530524A5 JP2011530524A5 (en11) 2012-09-13
JP5785077B2 true JP5785077B2 (ja) 2015-09-24

Family

ID=41401614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522218A Active JP5785077B2 (ja) 2008-08-05 2009-08-05 崩壊温度より高温での凍結乾燥

Country Status (6)

Country Link
US (1) US9884019B2 (en11)
EP (2) EP2323629B1 (en11)
JP (1) JP5785077B2 (en11)
CA (1) CA2729972C (en11)
ES (2) ES2968301T3 (en11)
WO (1) WO2010017296A1 (en11)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665902A1 (en) * 2006-10-03 2008-04-10 Wyeth Lyophilization methods and apparatuses
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
EP2187932B1 (en) 2007-08-07 2015-01-28 DePuy Synthes Products, LLC Protein formulations comprising gdf-5 in aqueous acidic solution
WO2009129101A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
US11576863B2 (en) 2013-03-15 2023-02-14 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
EP3123090A4 (en) * 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Lyophilized factor ix formulations
EP3323410A1 (en) * 2016-11-22 2018-05-23 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Pharmaceutical parenteral formulation containing carglumic acid
CN107543373B (zh) * 2017-09-06 2019-04-26 华派生物工程集团有限公司 一种活疫苗的冷冻干燥方法
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
CN109369821B (zh) * 2018-11-28 2021-12-14 四川恒通动保生物科技有限公司 一种黄芪多糖的高效提取制备方法
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
CA3168873A1 (en) * 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Target residual moisture content for lyophilized drug product

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
EP0762869A1 (en) * 1994-06-03 1997-03-19 The Procter & Gamble Company Fast dissolving dosage forms
DE60035260T2 (de) * 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
CA2569276C (en) * 2004-06-02 2018-01-23 Victor Bronshtein Preservation by vaporization
DE602005022895D1 (de) * 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
WO2006081320A2 (en) * 2005-01-27 2006-08-03 Human Genome Sciences, Inc. Pharmaceutical formulation
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof

Also Published As

Publication number Publication date
ES2755029T3 (es) 2020-04-21
EP2323629B1 (en) 2019-10-09
CA2729972A1 (en) 2010-02-11
EP3572073A1 (en) 2019-11-27
ES2968301T3 (es) 2024-05-08
CA2729972C (en) 2018-11-20
EP2323629A1 (en) 2011-05-25
JP2011530524A (ja) 2011-12-22
US20100041870A1 (en) 2010-02-18
EP3572073B1 (en) 2023-12-20
EP3572073C0 (en) 2023-12-20
US9884019B2 (en) 2018-02-06
WO2010017296A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
JP5785077B2 (ja) 崩壊温度より高温での凍結乾燥
Bjelošević et al. Excipients in freeze-dried biopharmaceuticals: Contributions toward formulation stability and lyophilisation cycle optimisation
Mensink et al. How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions
US10639362B2 (en) Pharmaceutical compositions containing Clostridium difficile toxoids A and B
ES2434840T3 (es) Formulación de proteína liofilizada isotónica estable
Ayensu et al. Development and physico-mechanical characterisation of lyophilised chitosan wafers as potential protein drug delivery systems via the buccal mucosa
CA2721019C (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
Haeuser et al. Excipients for room temperature stable freeze-dried monoclonal antibody formulations
JP2013100329A (ja) 薬学的製剤
JP2012530721A (ja) 小モジュール免疫薬のための凍結乾燥製剤
PT1771208E (pt) Utilização de derivados de tioflavina radiorotulados em imagiologia amiloide para avaliar terapias anti-amiloide
KR20090007588A (ko) 니코틴-담체 백신 제제
JP2008510716A (ja) Ｉｌ−１アンタゴニスト製剤
JP2011530524A5 (en11)
KR20190066014A (ko) 실온 안정성 동결건조된 단백질
US11713922B2 (en) Target residual moisture content for lyophilized drug product
JP2023085555A (ja) 抗Ｈｅｒ２抗体薬物コンジュゲートの製剤
JP2018535242A (ja) 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比
CN108379561A (zh) 一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法
Wei et al. Developing biologics tablets: the effects of compression on the structure and stability of bovine serum albumin and lysozyme
AU2004206844A1 (en) Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
Pardeshi et al. Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review
JP7025928B2 (ja) 外科的介入後の腹膜の癒着を予防または治療するための医薬組成物および医薬組成物の使用
KR20240099278A (ko) 에프룩시페르민의 제약 조성물
VARASTEH et al. Optimization of anti-Rh D immunoglobulin stability in the lyophilization processes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120730

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150723

R150 Certificate of patent or registration of utility model

Ref document number: 5785077

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250